Moderna Stock Jumps as Biotech Gets $590M From US To …
5 days ago · Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech firm's mRNA-1018 candidate posted positive ...
Moderna Secures $590M Funding From U.S. Government for Bird …
Jan 20, 2025 · This is the second time under a year that Moderna has secured funding from the U.S. government for its bird flu vaccine. Last July, the company was awarded $176 million by the U.S. government to ...
Moderna Announces Updates on Pandemic Influenza Program
CAMBRIDGE, MA / January 17, 2025 / Moderna, Inc. (NASDAQ: MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA ...
Moderna, Inc. (MRNA) Latest Stock News & Headlines - Yahoo …
Get the latest Moderna, Inc. (MRNA) stock news and headlines to help you in your trading and investing decisions.
Moderna R&D day: $1 billion in cost cuts, 10 product launches
Sep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline …
News Details - Moderna
Mar 27, 2024 · Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints. Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV.
News Details - Moderna
Jun 10, 2024 · CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial.
News Details - Moderna
Jan 8, 2024 · CAMBRIDGE, MA / ACCESSWIRE / January 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress on the Company's pipeline of transformative mRNA medicines. Moderna enters 2024 with 45 therapeutic and vaccine programs, nine of which are in late-stage development.
Moderna Awarded Tender for the Supply of Its mRNA ... - Markets …
2 days ago · This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna securing an ...
Moderna jumps as vaccine shows benefit in head and neck cancer …
Apr 9, 2024 · Moderna shares rose 8% to a three-month high on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a...